CHEK1 and small cell lung carcinoma: The current study adds to our prior analyses of CHK1 and PARP inhibition on the immune microenvironment of SCLC (Sen et al., 2019a, 2019b) and nominates WEE1 as a therapeutic target with immune-modifying activity.